SAS Output

23-FEB-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC STUDIES ONLY (TXCA=Y)

15% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1558 144 9% 973 -584 903 -655
ERLYTX 76 19 25% 128 52 270 194
GI 476 10 2% 67 -408 101 -375
GU 450 75 17% 506 56 412 -38
GYN 57 0 0% 0 -57 0 -57
LEUK 150 9 6% 60 -89 120 -30
LUNG 524 26 5% 175 -348 211 -313
LYMPH 172 7 4% 47 -124 32 -140
MELAN 55 15 27% 101 46 98 43
MMYEL 147 11 7% 74 -72 102 -45
OTHER 0 2   13 13 49 49
SXQOL 0 1   6 6 12 12
Total 3665 319   2150 -1509 2310 -1355

23-FEB-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES ONLY (TXCA=N)

15% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 3   20 20 3 3
BREAST 37 72 195% 486 449 376 339
CCD 0 241   1628 1628 1542 1542
GU 0 0   0 0 0 0
LEUK 69 7 10% 47 -21 19 -50
LUNG 43 52 121% 351 308 576 533
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 0   0 0 3 3
PREV 0 5   33 33 45 45
SURV 0 29   196 196 136 136
SXQOL 878 1 0% 6 -871 5 -873
Total 1172 410   2767 1597 2705 1533

23-FEB-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS

15% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 3   20 20 3 3
BREAST 1595 216 14% 1460 -135 1279 -316
CCD 0 241   1628 1628 1542 1542
ERLYTX 76 19 25% 128 52 270 194
GI 476 10 2% 67 -408 101 -375
GU 450 75 17% 506 56 412 -38
GYN 57 0 0% 0 -57 0 -57
LEUK 219 16 7% 108 -110 139 -80
LUNG 567 78 14% 527 -39 787 220
LYMPH 225 7 3% 47 -177 32 -193
MELAN 55 15 27% 101 46 98 43
MMYEL 239 11 5% 74 -164 102 -137
OTHER 0 2   13 13 52 52
PREV 0 5   33 33 45 45
SURV 0 29   196 196 136 136
SXQOL 878 2 0% 13 -864 17 -861
Total 4837 729   4921 90 5015 178

23-FEB-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

THERAPEUTIC REGISTRATIONS BY SWOG INSTITUTIONS ONLY (TXCA=Y)

15% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 1012 95 9% 642 -369 594 -418
ERLYTX 76 16 21% 108 32 180 104
GI 418 7 2% 47 -370 82 -336
GU 375 51 14% 344 -30 264 -111
GYN 57 0 0% 0 -57 0 -57
LEUK 122 9 7% 60 -61 84 -38
LUNG 441 23 5% 155 -285 175 -266
LYMPH 129 6 5% 40 -88 29 -100
MELAN 55 11 20% 74 19 71 16
MMYEL 85 10 12% 67 -17 94 9
OTHER 0 2   13 13 49 49
SXQOL 0 1   6 6 12 12
Total 2770 231   1556 -1207 1634 -1136

23-FEB-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

NON-THERAPEUTIC STUDIES FOR SWOG INSTITUTIONS ONLY (TXCA=N)

15% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 3   20 20 3 3
BREAST 10 72 720% 486 476 376 366
CCD 0 183   1236 1236 1187 1187
GU 0 0   0 0 0 0
LEUK 69 7 10% 47 -21 19 -50
LUNG 30 50 167% 337 307 422 392
LYMPH 53 0 0% 0 -53 0 -53
MMYEL 92 0 0% 0 -92 0 -92
OTHER 0 0   0 0 3 3
PREV 0 5   33 33 34 34
SURV 0 20   135 135 91 91
SXQOL 740 1 0% 6 -733 5 -735
Total 994 341   2300 1308 2140 1146

23-FEB-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS BY SWOG INSTITUTIONS ONLY

15% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
  0 3   20 20 3 3
BREAST 1022 167 16% 1128 106 970 -52
CCD 0 183   1236 1236 1187 1187
ERLYTX 76 16 21% 108 32 180 104
GI 418 7 2% 47 -370 82 -336
GU 375 51 14% 344 -30 264 -111
GYN 57 0 0% 0 -57 0 -57
LEUK 191 16 8% 108 -82 103 -88
LUNG 471 73 15% 493 22 597 126
LYMPH 182 6 3% 40 -141 29 -153
MELAN 55 11 20% 74 19 71 16
MMYEL 177 10 6% 67 -109 94 -83
OTHER 0 2   13 13 52 52
PREV 0 5   33 33 34 34
SURV 0 20   135 135 91 91
SXQOL 740 2 0% 13 -726 17 -723
Total 3764 572   3859 101 3774 10

23-FEB-2019 6:10

SWOG CURRENT AND PROJECTED ACCRUAL BY COMMITTEE

ALL ACCRUAL REGISTRATIONS TO CANCER CONTROL STUDIES

15% of Calendar Year is Past

The REPORT Procedure

Detailed and/or summarized report

Table 1

COMMITTEE Base Accrual
2010
2019
Accrual
to date
Percentage
of Base
Accrual
Projected
2019
Accrual
Projected
Increase
<Decrease>
from Base
Accrual
Last
12 Months
12 Month
Increase
<Decrease>
from Base
BREAST 65 127 195% 858 793 785 720
CCD 0 241   1628 1628 1542 1542
GI 81 1 1% 6 -74 43 -38
GU 215 58 27% 392 177 272 57
LEUK 0 7   47 47 19 19
LUNG 53 0 0% 0 -53 11 -42
LYMPH 7 0 0% 0 -7 0 -7
MELAN 0 3   20 20 9 9
MMYEL 0 7   47 47 82 82
OTHER 0 2   13 13 11 11
PREV 0 5   33 33 45 45
SURV 0 29   196 196 136 136
SXQOL 878 2 0% 13 -864 17 -861
Total 1299 482   3253 1956 2972 1673

23-FEB-2019 6:10

SWOG OPEN AND TEMPORARILY CLOSED STUDIES

The REPORT Procedure

Detailed and/or summarized report

Table 1

Comm. Phase Study Stat
Center
Open
Date
Months
Open
Total
Regs
Accrual
Goal
Monthly
Accrual
Rate
Date of
Expected Closure or
Temporary Closure
    EA8171 ECOG-ACR     2      
    EA9161 ECOG-ACR     1      
BREAST II NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG 13APR2017:00:00:00   6   0.7  
    S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 SWOG 07JUL2016:00:00:00 31 301 333 8.7 May-2019
    S1706 Breast, Inflammatory, RT +/- Olaparib SWOG 12SEP2018:00:00:00 5 2 300 0.4 > 15 Yrs
  II-III NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG 24DEC2014:00:00:00   1   0.0  
  III A011106 Breast, Neoadj, ALTERNATE study ALLIANCE 15FEB2014:00:00:00   85   1.8  
    A011401 Breast, adj, Stage II/III HER2-, weight loss ALLIANCE 29AUG2016:00:00:00   213   7.0  
    A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo ALLIANCE 08DEC2016:00:00:00   78   4.7  
    B51 Breast, Regional Nodal XRT NRG 22AUG2013:00:00:00   33   0.7  
    B55 Brst, Adj Olaparib for BRCA,TNBC NRG 03JUL2014:00:00:00   33   0.5  
    EA1151 Brst, Tomosynthesis Mammographic Screening ECOG-ACRIN 06JUL2017:00:00:00   324   26.0  
    NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG 22JAN2015:00:00:00   69   1.7  
    S1207 Brst,Adj,Endocrine+/-Everolimus SWOG 03SEP2013:00:00:00 65 1856 1900 29.3 Mar-2019
    S1222 Brst,Fulv. +/- Ever. +/- Anastr. SWOG 09MAY2014:00:00:00   37 840   Feb-2015 Temp Close
    S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) SWOG 15NOV2016:00:00:00 27 380 1000 21.5 Jun-2021
  OTHER A221405 Breast, ET interruption, Pregnancy Outcomes ALLIANCE 15OCT2015:00:00:00   13   0.2  
    E1Z11 Brst,Genetic Predictors of AIMSS ECOG-ACRIN 10MAY2013:00:00:00   156   0.5  
CCD III A011104 Preoperative Breast MRI ALLIANCE 21FEB2014:00:00:00   19   0.8  
    A191402C PROS, Testing Decision Aids for Minority Men ALLIANCE 14JUL2017:00:00:00   17   1.3  
    S1415CD TrACER CSF Standing Order Intervention for FN SWOG 01SEP2016:00:00:00 29 2693 3960 107.2 Jan-2020
    S1703 Met Breast, STM-monitoring v Usual Care SWOG 16JUL2018:00:00:00 7 2 1056 0.3 > 15 Yrs
  OTHER ACCL16N1 Guideline Consistent Treatment AYA ALL COG 18DEC2017:00:00:00   34   5.7  
    EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer ECOG-ACRIN 17MAY2018:00:00:00   18   2.5  
ERLYTX II A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib ALLIANCE 06AUG2015:00:00:00   5   0.0  
    S1609 Rare Tumor, Comb Nivo/Ipi SWOG 13JAN2017:00:00:00 25 557 707 5.7 Apr-2021
  II-III ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) COG 16MAY2014:00:00:00   9   0.0  
  OTHER EAY131 MATCH ECOG-ACRIN 12AUG2015:00:00:00   142   4.2  
GI II A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT ALLIANCE 01DEC2016:00:00:00   15   0.0  
    EA2142 GI NEC, Adv G3, EP vs TMZ + CAP ECOG-ACRIN 06NOV2015:00:00:00   4   0.0  
    EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128 ECOG-ACRIN 01FEB2017:00:00:00   1   0.2  
    EA2165 Anal, Stg II-III, Nivolumab after CMT ECOG-ACRIN 13APR2018:00:00:00   2   0.3  
    S1613 mCRC, Adv/Met, TP vs CETIRI SWOG 09OCT2017:00:00:00 16 18 130 1.7 Sep-2024
  III A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC ALLIANCE 12SEP2017:00:00:00   10   0.8  
    NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG 07NOV2017:00:00:00   5   0.5  
    S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel SWOG 03DEC2018:00:00:00 2 3 268    
GU II A031701 Bladder, ddGC for MIBC with DDR Tumor Alt ALLIANCE 01AUG2018:00:00:00   1   0.2  
    EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) ECOG-ACRIN 08FEB2018:00:00:00   4   0.3  
    S1500 pRCC,Adv, Sunitinib vs MET inhib SWOG 05APR2016:00:00:00 34 119 148 2.5 Jan-2020
    S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab SWOG 07FEB2017:00:00:00 24 122 162 9.3 Jun-2019
  II-III NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG 30DEC2016:00:00:00   2   0.2  
  III A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) ALLIANCE 01JUL2015:00:00:00   4   0.2  
    A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs ALLIANCE 21SEP2017:00:00:00   25   3.0  
    EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) ECOG-ACRIN 02FEB2017:00:00:00   26   1.8  
    R0924 Pros, NADT+WPRT vs. NADT+P&SV RT NRG 07JUL2011:00:00:00   92   0.8  
    S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG SWOG 07FEB2017:00:00:00 24 237 969 15.8 Dec-2022
    S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum SWOG 17SEP2018:00:00:00 5 35 1273 6.7 > 15 Yrs
LEUK I S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP SWOG 01APR2014:00:00:00 58 49 38 1.3 Jun-2018
  I-II S1318 ALL, Age 65+, Ph±, Blinatumomab SWOG 12JAN2015:00:00:00   47 44   Sep-2017 Temp Close
  II S1712 CML, chronic phase, TKI +/- Ruxolitinib SWOG 20JUL2018:00:00:00 7 3 84 0.5 Aug-2032
  II-III S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics SWOG 22DEC2017:00:00:00   78 1670   Temp Close
  III A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo ALLIANCE 01JUN2017:00:00:00   1   0.2  
    E1910 BCR-ABL-neg, B ALL, Blinatumomab ECOG-ACRIN 23DEC2013:00:00:00   106   2.3  
    E2906 AML, Age 60+, Clo vs Dauno+Cy ECOG-ACRIN 24FEB2011:00:00:00   75   0.0  
  OTHER NHLBIMDS LEUK, National MDS Study ECOG-ACRIN 05APR2016:00:00:00   26   1.7  
LUNG II S1400F Non-Match: MEDI4736 + Tremelimumab SWOG 02OCT2017:00:00:00 16 56 132 4.5 Jun-2020
    S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac SWOG 09AUG2018:00:00:00 6 0 66 0.0 > 15 Yrs
    S1900A LOH and/or BRCA: Rucaparib SWOG 28JAN2019:00:00:00 0 0 88    
  II-III NRGCC003 SCLC, PCI or HA-PCI NRG 07DEC2015:00:00:00   4   0.0  
  III A081105 ALCHEMIST1, EGFR mut, Erlotinib ALLIANCE 02JAN2014:00:00:00   48   1.3  
    C30610 SCLC, Thoracic RT ALLIANCE 21MAR2008:00:00:00   56   0.0  
    E4512 ALCHEMIST2, ALK mut, Crizotinib ECOG-ACRIN 18AUG2014:00:00:00   12   0.5  
    EA5142 ALCHEMIST3, Non-match, Nivolumab ECOG-ACRIN 16MAY2016:00:00:00   93   4.7  
  OTHER A151216 ALCHEMIST0 - screening ALLIANCE 06FEB2014:00:00:00   664   14.2  
    LUNGMAP NSCLC, Adv, Master SWOG 28JAN2019:00:00:00 0 20      
  PILOT S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC SWOG 03NOV2017:00:00:00 15 10 28 1.0 Jul-2020
LYMPH II S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob SWOG 10AUG2017:00:00:00 18 14 150 1.3 Jul-2027
  III A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo ALLIANCE 15JUL2016:00:00:00   6   0.0  
    EA4151 Lymph, AHCT +/-Ritux, MRD Neg ECOG-ACRIN 29AUG2017:00:00:00   20   2.0  
MELAN II S1320 Adv, BRAF mut, Inter v Contin SWOG 22JUL2014:00:00:00 55 241 248 3.3 Apr-2019
    S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) SWOG 20OCT2016:00:00:00 28 19 77 0.8 Nov-2024
    S1607 MELAN, Adv, T-VEC, MK-3475 SWOG 02OCT2017:00:00:00 16 12 64 1.7 Sep-2021
    S1616 MELAN, Adv, Ipilimumab ± Nivolumab SWOG 17JUL2017:00:00:00 19 30 94 1.3 Jan-2023
    S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab SWOG 06DEC2018:00:00:00 2 1 556    
  II-III EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim ECOG-ACRIN 01MAR2016:00:00:00   36   0.0  
  III EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T ECOG-ACRIN 15DEC2015:00:00:00   33   1.0  
MMYEL II S1702 AL Amyloidosis, Relapsed, Isatuximab SWOG 08MAR2018:00:00:00 11 20 39 2.7 Sep-2019
  III E1A11 MM, frontline, BLD vs CLD ECOG-ACRIN 22NOV2013:00:00:00   259   8.0  
OTHER II A091401 Sarc, ALLIANCE 18JUN2015:00:00:00   10   0.0  
    EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp ECOG-ACRIN 29MAR2016:00:00:00   12   0.5  
    EAF151 Brain, GBM, Bev, Blood Volume ECOG-ACRIN 14APR2017:00:00:00   2   0.0  
    NRGBN001 HN, novel vs. std chemoradiation + chemo NRG 28AUG2015:00:00:00   1   0.0  
  II-III NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG 06FEB2016:00:00:00   3   0.0  
    NRGGY009 Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev NRG 12MAY2017:00:00:00   6   1.0  
    NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG 21APR2014:00:00:00   6   0.2  
    R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux NRG 18MAR2013:00:00:00   3   0.0  
  III G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT NRG 12APR2010:00:00:00   1   0.0  
    N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC ALLIANCE 22SEP2009:00:00:00   7   0.0  
    R0724 Cervical, Chem+RT +/- Adj. Chemo NRG 15JAN2014:00:00:00   1   0.0  
  OTHER EAQ152 Communication & education in tumor profiling ECOG-ACRIN 26SEP2016:00:00:00   14   0.3  
PREV III A211102 Breast, Atypia via RPFNA, Metformin v Placebo ALLIANCE 01FEB2015:00:00:00   3   0.0  
    S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac SWOG 01MAR2013:00:00:00 71 231 480 3.5 Jan-2025
SURV III E1Q11 EROS: Reproductive Health in Cancer Survivors ECOG-ACRIN 30SEP2015:00:00:00   19   1.2  
    S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol SWOG 15SEP2017:00:00:00 17 76 817 8.7 Mar-2026
  OTHER EA9131 Leuk, Strategy to decrease early APL deaths ECOG-ACRIN 16AUG2017:00:00:00   22   2.0  
    S1316 Compar. Effectiv. Trial for MBO SWOG 09MAR2015:00:00:00 47 176 200 2.8 Oct-2019
SXQOL III A221101 Glioma, Nuvigil/Placebo Fatigue ALLIANCE 03JUN2013:00:00:00   21   0.0  
    A221505 Brst, Hypofractionated Post Mast Rad ALLIANCE 01FEB2018:00:00:00   7   0.8  
    S1600 Bladder,Radical Cystectomy Outcomes Nutrition SWOG 21FEB2019:00:00:00 0 0 200    
    S1614 HBV in Ca Pts, TAF vs SOC SWOG 21FEB2019:00:00:00 0 0 444    
  PILOT A221504 NSCL, Advanced, placebo vs naloxegol ALLIANCE 13OCT2017:00:00:00   2   0.3  
 
Accrual goals assume studies are not terminated early as a result of interim analysis.
Studies may have accrual objectives specific to subsets of patients and are not reflected in this report.
Monthly accrual rate is projected from accrual in the previous six months for studies open at least three months.
Expected closure dates are calculated for SWOG coordinated studies that have been open at least three months.

23-FEB-2019 6:10

OPEN AND TEMPORARILY CLOSED STUDIES: BY STUDY TYPE, COMMITTEE, INTERGROUP, SWOG/OTHER STAT CENTER

The REPORT Procedure

Detailed and/or summarized report

Table 1

Phase Comm. Int
grp
Stat
Center
Study NCIPROTO CA
Cntrl
Study
Temp
Close
OTHER BREAST Y ECOG-ACRIN E1Z11 Brst,Genetic Predictors of AIMSS E1Z11 Y  
    Y ALLIANCE A221405 Breast, ET interruption, Pregnancy Outcomes A221405 Y  
  CCD Y COG ACCL16N1 Guideline Consistent Treatment AYA ALL ACCL16N1CD Y  
    Y ECOG-ACRIN EAQ162CD CCD, Financial Burden, Colon & Rectal Cancer EAQ162CD Y  
  ERLYTX Y ECOG-ACRIN EAY131 MATCH EAY131 N  
  LEUK Y ECOG-ACRIN NHLBIMDS LEUK, National MDS Study NHLBI-MDS Y  
  LUNG Y SWOG LUNGMAP NSCLC, Adv, Master LUNGMAP N  
    Y ALLIANCE A151216 ALCHEMIST0 - screening A151216 N  
  OTHER Y ECOG-ACRIN EAQ152 Communication & education in tumor profiling EAQ152 Y  
  SURV Y SWOG S1316 Compar. Effectiv. Trial for MBO S1316 Y  
    Y ECOG-ACRIN EA9131 Leuk, Strategy to decrease early APL deaths EA9131 Y  
I LEUK N   S1312 ALL, CD22+, REL/REF, Inotuzumab+CVP   N  
I-II LEUK Y SWOG S1318 ALL, Age 65+, Ph±, Blinatumomab S1318 N Y
II BREAST Y SWOG S1416 Brst, TNBC/BRCA, Cis+/- ABT-888 S1416 N  
    Y SWOG S1706 Breast, Inflammatory, RT +/- Olaparib S1706 N  
    Y NRG NRGBR005 Br, Stg II&IIIA, Post NAdj Chemo Br Conserv NRG-BR005 N  
  ERLYTX Y SWOG S1609 Rare Tumor, Comb Nivo/Ipi S1609 N  
    Y ALLIANCE A071401 Prog Meningiomas,SMO/AKT/NF2 Inhib A071401 N  
  GI Y SWOG S1613 mCRC, Adv/Met, TP vs CETIRI S1613 N  
    Y ECOG-ACRIN EA2161 PANC, Adv Rapalog Resistant PNETs, MLN0128 EA2161 N  
    Y ECOG-ACRIN EA2142 GI NEC, Adv G3, EP vs TMZ + CAP EA2142 N  
    Y ECOG-ACRIN EA2165 Anal, Stg II-III, Nivolumab after CMT EA2165 N  
    Y ALLIANCE A021501 Adeno Panc,Borderline Resect,Chemo vs ChemoRT A021501 N  
  GU Y SWOG S1500 pRCC,Adv, Sunitinib vs MET inhib S1500 N  
    Y SWOG S1605 Blad, BCG-Unresponsive NMIBC, Atezolizumab S1605 N  
    Y ECOG-ACRIN EA8153 Pros, ADT + Abira +/- Cabazitaxel (CHAARTED2) EA8153 N  
    Y ALLIANCE A031701 Bladder, ddGC for MIBC with DDR Tumor Alt A031701 N  
  LEUK Y SWOG S1712 CML, chronic phase, TKI +/- Ruxolitinib S1712 N  
  LUNG Y SWOG S1900A LOH and/or BRCA: Rucaparib S1900A N  
    Y SWOG S1400F Non-Match: MEDI4736 + Tremelimumab S1400F N  
    Y SWOG S1701 Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac S1701 N  
  LYMPH Y SWOG S1608 FL, TGR-1202/Lenalidomide/CHOP or Benda +Ob S1608 N  
  MELAN Y SWOG S1320 Adv, BRAF mut, Inter v Contin S1320 N  
    Y SWOG S1801 Melan, Adv, Adj vs Neoadj Pembrolizumab S1801 N  
    Y SWOG S1607 MELAN, Adv, T-VEC, MK-3475 S1607 N  
    Y SWOG S1616 MELAN, Adv, Ipilimumab ± Nivolumab S1616 N  
    Y SWOG S1512 Melan, Adv, Desmoplastic, MK-3475 (pembro) S1512 N  
  MMYEL Y SWOG S1702 AL Amyloidosis, Relapsed, Isatuximab S1702 N  
  OTHER Y NRG NRGBN001 HN, novel vs. std chemoradiation + chemo NRG-BN001 N  
    Y ALLIANCE A091401 Sarc, A091401 N  
    Y ECOG-ACRIN EA3132 HN SCC, Stg III-IV , Adj RT +/- Cisp EA3132 N  
    Y ECOG-ACRIN EAF151 Brain, GBM, Bev, Blood Volume EAF151 N  
PILOT LUNG Y SWOG S1619 Meso,Stg I-III, Nadj chemo/Atezmb->Atezmb+SOC S1619 N  
  SXQOL Y ALLIANCE A221504 NSCL, Advanced, placebo vs naloxegol A221504 Y  
II-III BREAST Y NRG NRGBR002 Brst, OMBC, II-III, SoC +/- SBRT and/or SA NRG-BR002 N  
  ERLYTX Y COG ARST1321 NonRhabdo STS,Pazopanib (PAZNTIS) ARST1321 N  
  GU Y NRG NRGGU002 Pros, RT + ADT After RP +/- Adj Docetaxel NRG-GU002 N  
  LEUK Y SWOG S1612 AML/MDS, Age 60+, Aza/Novel Therapeutics S1612 N Y
  LUNG Y NRG NRGCC003 SCLC, PCI or HA-PCI NRG-CC003 Y  
  MELAN Y ECOG-ACRIN EA6141 Melan, Avd, Nivolumab+Ipi ± Sargmostim EA6141 N  
  OTHER Y NRG NRGGY009 Ovar, PLD/Atexo vs PLD/Atezo/Bev vs PLD/Bev NRG-GY009 Y  
    Y NRG NRGGY005 OVAR, Cedir vs Olaparib vs C+O vs Std of Care NRG-GY005 Y  
    Y NRG R1216 HN, Adv,Cis vs Dtx vs Dtx+Cetux RTOG-1216 Y  
    Y NRG NRGHN001 Nasopharyngeal , Indiviual Tx EBV NRG-HN001 Y  
III BREAST N   S1222 Brst,Fulv. +/- Ever. +/- Anastr.   N Y
    Y SWOG S1207 Brst,Adj,Endocrine+/-Everolimus S1207 Y  
    Y SWOG S1418 Breast, Adj, TNBC, MK-3475 (Pembrolizumab) S1418 Y  
    Y ALLIANCE A011106 Breast, Neoadj, ALTERNATE study A011106 N  
    Y NRG B51 Breast, Regional Nodal XRT NSABP-B-51 Y  
    Y ALLIANCE A011401 Breast, adj, Stage II/III HER2-, weight loss A011401 Y  
    Y NRG NRGBR003 Brst,Adj,TNBC,AC -> WP +/- Carbo NRG-BR003 N  
    Y ALLIANCE A011502 Brst, Adj, Nodal+&HER2-, Aspirin vs. Placebo A011502 Y  
    Y ECOG-ACRIN EA1151 Brst, Tomosynthesis Mammographic Screening EA1151 N  
    Y NRG B55 Brst, Adj Olaparib for BRCA,TNBC NSABP-B-55 Y  
  CCD Y SWOG S1415CD TrACER CSF Standing Order Intervention for FN S1415CD Y  
    Y SWOG S1703 Met Breast, STM-monitoring v Usual Care S1703 Y  
    Y ALLIANCE A011104 Preoperative Breast MRI A011104 Y  
    Y ALLIANCE A191402C PROS, Testing Decision Aids for Minority Men A191402CD Y  
  GI Y SWOG S1815 Biliary, Met/LocAdv, GC+CPT±Nab-paclitaxel S1815 N  
    Y ALLIANCE A021502 Colon, Stg III, Chemo +/- Atezol, ATOMIC A021502 Y  
    Y NRG NRGGI004 Colorectal, Stg IV, dMMR Immuno-Therapy NRG-GI004 Y  
  GU Y SWOG S1802 Pros, Stg IV, SST +/- Surg/RT to Primary Tum S1802 Y  
    Y SWOG S1602 Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG S1602 Y  
    Y NRG R0924 Pros, NADT+WPRT vs. NADT+P&SV RT RTOG-0924 Y  
    Y ECOG-ACRIN EA8143 RCC, HR, Surg +/- Nivolumab (PROSPER) EA8143 Y  
    Y ALLIANCE A031501 Bladder, MIBC/Loc Adv, Adjv Pembro vs Obs A031501 Y  
    Y ALLIANCE A031102 GCT, Recur, Std Chemo(TIP) vs HD Chemo(TI-CE) A031102 Y  
  LEUK Y ECOG-ACRIN E2906 AML, Age 60+, Clo vs Dauno+Cy E2906 Y  
    Y ECOG-ACRIN E1910 BCR-ABL-neg, B ALL, Blinatumomab E1910 N  
    Y ALLIANCE A041501 B-Cell ALL, Frontline Tx +/- Intuzumab Ozo A041501 N  
  LUNG Y ALLIANCE C30610 SCLC, Thoracic RT CALGB-30610 Y  
    Y ALLIANCE A081105 ALCHEMIST1, EGFR mut, Erlotinib A081105 N  
    Y ECOG-ACRIN EA5142 ALCHEMIST3, Non-match, Nivolumab EA5142 N  
    Y ECOG-ACRIN E4512 ALCHEMIST2, ALK mut, Crizotinib E4512 N  
  LYMPH Y ECOG-ACRIN EA4151 Lymph, AHCT +/-Ritux, MRD Neg EA4151 N  
    Y ALLIANCE A051301 ABC DLBCL, Auto HCT and Ibrutinib/Placebo A051301 N  
  MELAN Y ECOG-ACRIN EA6134 Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T EA6134 Y  
  MMYEL Y ECOG-ACRIN E1A11 MM, frontline, BLD vs CLD E1A11 Y  
  OTHER Y ALLIANCE N0577 BRN, Glio,Tem vs Tem+RT vsRT+PVC N0577 N  
    Y NRG G0263 Cerv, Stg I/IIA, adjv RT vs chemoRT GOG-0263 Y  
    Y NRG R0724 Cervical, Chem+RT +/- Adj. Chemo RTOG-0724 Y  
  PREV Y SWOG S0820 PACES: ColrecStg0-3 Blind DFMO/Sulindac S0820 Y  
    Y ALLIANCE A211102 Breast, Atypia via RPFNA, Metformin v Placebo A211102 Y  
  SURV Y SWOG S1501 Surv, Breast Stg IV, Card Tox w/ Carvedilol S1501 Y  
    Y ECOG-ACRIN E1Q11 EROS: Reproductive Health in Cancer Survivors E1Q11 Y  
  SXQOL Y SWOG S1600 Bladder,Radical Cystectomy Outcomes Nutrition S1600 Y  
    Y SWOG S1614 HBV in Ca Pts, TAF vs SOC S1614 Y  
    Y ALLIANCE A221101 Glioma, Nuvigil/Placebo Fatigue A221101 Y  
    Y ALLIANCE A221505 Brst, Hypofractionated Post Mast Rad A221505 Y  
    Y ECOG-ACR EA8171 EA8171    
    Y ECOG-ACR EA9161 EA9161